2,3-二氯-4-氟代-N-乙酰苯胺 | 96980-64-2

• 物质功能分类: 有机原料 - 氨基化合物
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氯-4-氟代-N-乙酰苯胺
• 中文别名: 3-氯-N-氯乙酰基-4-氟苯胺；3-氯-N-(氯乙酰)-4-氟苯胺；新戊烷；N1-(3-氯-4-氟苯基)-2-氯乙胺；2,3'-二氯-4-氟代-N-乙酰苯胺
• 英文名称: N-(2-chloroacetyl)-3-chloro-4-fluoroaniline
• 英文别名: 2-chloro-N-(3-chloro-4-fluorophenyl)acetamide
• CAS: 96980-64-2
• 化学式: C₈H₆Cl₂FNO
• mdl: MFCD00084938
• 分子量: 222.046
• InChiKey: DJPAQYXQRCWKEH-UHFFFAOYSA-N

物化性质

• 熔点：
  96 °C
• 沸点：
  363.2±42.0 °C(Predicted)
• 密度：
  1.479±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.8
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

安全信息

• 危险等级：
  IRRITANT
• 危险品标志：
  Xi
• 危险类别码：
  R20/21/22
• 海关编码：
  2924299090
• 安全说明：
  S26,S36/37/39
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P201,P202,P261,P264,P270,P271,P280,P302+P352,P304+P340,P308+P313,P310,P361,P403+P233,P405,P501
• 危险品运输编号：
  2811
• 危险性描述：
  H301,H311,H331,H341
• 储存条件：
  室温下储存在惰性气体中。

SDS

Name:	N1-(3-chloro-4-fluorophenyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:	3-Chloro-N-chloroacetyl-4-fluoroanilin
CAS:	96980-64-2

Section 1 - Chemical Product MSDS Name:N1-(3-chloro-4-fluorophenyl)-2-chloroacetamide 97% Material Safety Data Sheet
Synonym:3-Chloro-N-chloroacetyl-4-fluoroanilin

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
96980-64-2	N1-(3-Chloro-4-fluorophenyl)-2-chloroa	97%	unlisted

Hazard Symbols: XN
Risk Phrases: 20/21/22 36/37/38

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed.
Irritating to eyes, respiratory system and skin.
Potential Health Effects
Eye:
Causes eye irritation.
Skin:
Causes skin irritation. Harmful if absorbed through the skin.
Ingestion:
Harmful if swallowed. May cause irritation of the digestive tract.
Inhalation:
Harmful if inhaled. Causes respiratory tract irritation.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen. Get medical aid.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 96980-64-2: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: cream
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 98 - 101 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C8H6Cl2FNO
Molecular Weight: 222

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents, reducing agents, bases, amines.
Hazardous Decomposition Products:
Hydrogen chloride, chlorine, nitrogen oxides, carbon monoxide, carbon dioxide, fluorine, hydrogen fluoride gas.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 96980-64-2 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
N1-(3-Chloro-4-fluorophenyl)-2-chloroacetamide - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: XN
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 36/37/38 Irritating to eyes, respiratory system
and skin.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
WGK (Water Danger/Protection)
CAS# 96980-64-2: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 96980-64-2 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 96980-64-2 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氯-4-氟代-N-乙酰苯胺 在 劳森试剂 、 potassium carbonate 作用下， 以 N,N-二甲基甲酰胺 、 丙酮 、 甲苯 为溶剂， 反应 16.0h， 生成 4H-1,2,4-Triazole, 4-(3-chloro-4-fluorophenyl)-3-((4-chloro-3-methylphenoxy)methyl)-5-(4-fluorophenyl)-
  参考文献：
  名称：

  Bansal, O P; Srinivas, J S; Sastry, C V Reddy, Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 1992, vol. 31, # 4, p. 289 - 292

  摘要：

  DOI：
• 作为产物：
  描述：

  3-氯-4-氟苯胺 、 氯乙酰氯 在 溶剂黄146 作用下， 生成 2,3-二氯-4-氟代-N-乙酰苯胺
  参考文献：
  名称：

  Synthesis and Antimicrobial Activity ofSome New Thioether Derivatives of Quinoxaline

  摘要：

  2-氯-3-甲基喹喔啉被选为核心，围绕它进行分子操作，以获得预期具有更好抗微生物活性的新化合物。通过用硫醚键替换C-2处的氯原子合成了各种喹喔啉衍生物，这些衍生物又与2-（N-（取代苯基）乙酰胺）结合。合成的化合物（5）被测试其抗微生物活性。其中化合物5b、5c、5d和5i表现出最活性（与标准抗菌药环丙沙星相媲美）。这些化合物的结构是根据它们的光谱数据确认的。

  DOI：

  10.1155/2011/482831

文献信息

• Synthesis of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives as potent anti-inflammatory agents and inhibitors of monocyte-to-macrophage transformation
  作者：Malla Reddy Gannarapu、Sathish Babu Vasamsetti、Nagender Punna、Naresh Kumar Royya、Shanthan Rao Pamulaparthy、Jagadeesh Babu Nanubolu、Srigiridhar Kotamraju、Narsaiah Banda

  DOI：10.1016/j.ejmech.2013.12.053

  日期：2014.3

  A series of novel 1,2-benzothiazine 1,1-dioxide-3-ethanone oxime N-aryl acetamide ether derivatives 7a–h and 9a–h were synthesized starting from sodium salt of saccharin 1 in series of steps. Final compounds 7a–h and 9a–h were evaluated for the anti-inflammatory activity and their ability to inhibit monocyte-to-macrophage transformation. Compounds 7e, 9b, 9e and 9h showed impressive anti-inflammatory

  从糖精1的钠盐开始，按一系列步骤合成了一系列新颖的1,2-苯并噻嗪1,1-二氧化物-3-乙酮肟N-芳基乙酰胺醚衍生物7a – h和9a – h。评价了最终化合物7a – h和9a – h的抗炎活性及其抑制单核细胞向巨噬细胞转化的能力。化合物7e，9b，9e和9h在微摩尔浓度下显示出令人印象深刻的抗炎活性（TNF-α，IL-8和MCP-1），被发现比阳性对照（吡罗昔康）更好。化合物9e和化合物9h均显着抑制PMA诱导的MMP-9明胶酶活性。化合物9e和9h也极大地抑制了PMA诱导的单核细胞向巨噬细胞的转化，这是形成动脉粥样硬化的必要步骤。
• Acetamides and benzamides that are useful in treating sexual dysfunction
  申请人：——

  公开号：US20040029887A1

  公开（公告）日：2004-02-12

  The present invention relates to the use of compounds of formula (I) 1 for the treatment of sexual dysfunction and to compositions containing compounds of formula (I) for the treatment of sexual dysfunction.

  本发明涉及使用式(I)的化合物治疗性功能障碍，以及含有式(I)化合物的组合物用于治疗性功能障碍。
• 2-(3,4-Dihydro-4-Oxothieno[2,3-d]pyrimidin-2-ylthio) Acetamides as a New Class of Falcipain-2 Inhibitors. 3. Design, Synthesis and Biological Evaluation
  作者：Jin Zhu、Tong Chen、Jie Liu、Ruoqun Ma、Weiqiang Lu、Jin Huang、Honglin Li、Jian Li、Hualiang Jiang

  DOI：10.3390/molecules14020785

  日期：——

  The cysteine protease falcipain-2 (FP-2) of Plasmodium falciparum is a principal cysteine protease and an essential hemoglobinase of erythrocytic P. falciparum trophozoites, making it become an attractive target enzyme for developing anti-malarial drugs. In this study, a series of novel small molecule FP-2 inhibitors have been designed and synthesized based on compound 1, which was identified by using structure-based virtual screening in conjunction with an enzyme inhibition assay. All compounds showed high inhibitory effect against FP-2 with IC50s of 1.46-11.38 μM, and the inhibitory activity of compound 2a was ~2 times greater than that of prototype compound 1. The preliminary SARs are summarized and should be helpful for future inhibitor design, and the novel scaffold presented here, with its potent inhibitory activity against FP-2, also has potential application in discovery of new anti-malarial drugs.

  恶性疟原虫 (Plasmodium falciparum) 半胱氨酸蛋白酶 (falcipain-2， FP-2) 是原生质型疟原虫的主要半胱氨酸蛋白酶和必须的血红蛋白酶，这使得它成为研制抗疟药物的一个有吸引力的靶标酶。在本研究中，我们基于用酶抑制法结合基于结构的虚拟筛选得到的化合物 1，设计并合成了系列新型小分子 FP-2 抑制剂。所有化合物均为 FP-2的高效抑制剂，其半抑制浓度 (IC50) 值范围为 1.46 至 11.38 μM，化合物 2a 的抑制活性是母体化合物 1 的 2倍左右。本研究概括总结的初步构效关系将有助于未来抑制剂的设计，这里展示的新骨架以其对 FP-2的强效抑制活性，在发现新型抗疟药物方面也具有潜在的应用价值。
• N,3-Disubstituted 2-oxindole-1-carboxamides as analgesic and
  申请人：Pfizer Inc.

  公开号：US04569942A1

  公开（公告）日：1986-02-11

  Certain 2-oxindole-1-carboxamide compounds having an acyl substituent at the 3-position, and also further substituted on the carboxamide nitrogen by an alkyl, cycloalkyl, phenyl or substituted phenyl group, are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic and antiinflammatory agents in mammalian subjects. These 2-oxindole-1-carboxamide compounds are of particular value for ameliorating pain in human patients recovering from surgery or trauma, and alleviating the symptoms of chronic diseases, such as rheumatoid arthritis and osteoarthritis, in human subjects. Certain 2-oxindole-1-carboxamide compounds unsubstituted at C-3, but having a substituent on the carboxamide nitrogen, are useful as intermediates to the analgesic and antiinflammatory agents of the invention.

  某些在3位上具有酰基取代基，并且在羧酰胺氮上进一步被烷基、环烷基、苯基或取代苯基基团取代的2-噁嗪-1-羧酰胺化合物是环氧合酶（CO）和脂氧合酶（LO）酶的抑制剂，并且在哺乳动物主体中作为镇痛和抗炎药物是有用的。这些2-噁嗪-1-羧酰胺化合物对于缓解人类手术或创伤康复患者的疼痛以及减轻人类主体中慢性疾病的症状，如类风湿性关节炎和骨关节炎，具有特殊价值。某些在C-3位未取代的2-噁嗪-1-羧酰胺化合物，但在羧酰胺氮上具有取代基，作为本发明的镇痛和抗炎药物的中间体是有用的。
• 1,3-disubstituted 2-oxindoles as analgesic and anti-inflammatory agents
  申请人：Pfizer Inc.

  公开号：US04721712A1

  公开（公告）日：1988-01-26

  Certain 2-oxindole-1-carboxamide compounds having an acyl substituent at the 3-position, and also on the carboxamide nitrogen atom, are inhibitors of the cyclooxygenase (CO) and lipoxygenase (LO) enzymes, and are useful as analgesic agents and anti-inflammatory agents in mammalian subjects. These 2-oxindole-1-carboxamide compounds are of particular value for acute administration for ameliorating pain in human patients recovering from surgery or trauma, and also for chronic administration to human subjects for alleviating the symptoms of chronic diseases, such as rheumatoid arthritis and osteoarthritis. Certain 2-oxindole-1-carboxamide compounds unsubstituted at C-3, but having an acyl substituent on the carboxamide nitrogen atom, are useful as intermediates to the aforementioned analgesic and anti-inflammatory agents.

  某些在3位上具有酰基取代基，并且在羧酰胺氮原子上也有取代基的2-噁嗪-1-羧酰胺化合物是环氧合酶（CO）和脂氧合酶（LO）酶的抑制剂，并且在哺乳动物体内作为镇痛剂和抗炎剂具有用途。这些2-噁嗪-1-羧酰胺化合物对于急性给药用于缓解手术或创伤后人类患者的疼痛，以及对于慢性给药用于减轻慢性疾病症状，如类风湿性关节炎和骨关节炎的人类患者，具有特殊价值。某些在C-3位未取代的2-噁嗪-1-羧酰胺化合物，但在羧酰胺氮原子上具有酰基取代基，可作为上述镇痛剂和抗炎剂的中间体。